Roivant's CEO Says We're All Worried About the Wrong Thing

So when Gline says "red herring," a lot of people hear "denial."

The Law That Changed Everything

The anxiety isn't just about competition; it's about national security. The BIOSECURE Act, signed into law in December 2025 as part of the National Defense Authorization Act, bars U.S. federal agencies from contracting with entities that use services from designated Chinese "Biotechnology Companies of Concern."

The law doesn't just affect government labs. Because it covers anyone receiving federal funding (including companies billing Medicare and Medicaid), it sends ripple effects through the entire pharmaceutical supply chain. Nearly 80% of surveyed U.S. biotech companies rely on Chinese-owned or China-based manufacturers for some part of their operations. That's not a minor dependency; it's the foundation of how many drugs get made.

Companies tied to China's military-linked firms face immediate restrictions. Pre-existing contracts with other designated companies are grandfathered for five years from the date the relevant federal acquisition rules are revised. Either way, the BIOSECURE Act is forcing a massive, expensive rewiring of global pharma supply chains.

It's like discovering your favorite restaurant sources all its ingredients from a single supplier who just got shut down by the health department. You can still cook, but everything gets harder and more expensive overnight.

What Gline Might Actually Be Right About

Dismissing the contrarian view entirely would be a mistake, though. Gline runs a company with a $4.4 billion cash balance and a pipeline stacked with late-stage assets. Roivant's "Vant" model (spinning up focused subsidiaries to develop individual drugs) means the company can move fast without the bureaucratic drag of a traditional pharma giant.

The company expects 3+ product launches, 4+ regulatory filings, and 8+ pivotal study readouts over the next few years. Its lead asset, brepocitinib (a drug targeting two enzymes involved in inflammation), has an NDA filing expected in early 2026 for dermatomyositis, a rare muscle disease. A second Phase 3 trial in non-infectious uveitis (a type of eye inflammation) is also underway.

Roivant doesn't appear to have significant China partnerships or cross-border deals in its current portfolio. That context matters. When your own strategy doesn't depend on Chinese supply chains or licensing deals, it's a lot easier to call the whole debate a distraction.

Gline's deeper point may be this: spending all your energy worrying about a geopolitical chess match means you're not solving the problems right in front of you. The biotech talent shortage is real. The AI hype cycle is inflating expectations that could collapse painfully. These are fires burning in the house right now.

The $53 Billion Question

Analysts project that China could account for 35% of all FDA approvals by 2040. An April 2025 report from the National Security Commission on Emerging Biotechnology warned that losing the biopharmaceutical innovation edge could undermine U.S. leadership in the broader biotech space.

So is China a red herring? It depends on your vantage point. If you're Roivant, sitting on a pile of cash with a pipeline full of homegrown assets, maybe the noise really is overblown. If you're a mid-stage biotech relying on a Chinese CDMO (contract manufacturer) to make your drug substance, the BIOSECURE Act just made your life a lot more complicated.

The truth probably lives somewhere in the messy middle. China is not the apocalyptic threat that hawks describe, but it's also not the nothing-burger Gline implies. It's a competitor, a collaborator, and a geopolitical wildcard, all at once.

What's clear is that the industry can't afford to focus on just one problem. The talent crisis, AI's unfulfilled promises, supply chain dependencies, and yes, China's rise: they're all happening simultaneously. Calling any single one of them a red herring risks missing the bigger picture.

Gline threw a grenade into the conversation. Whether it clears a path forward or just creates more smoke remains to be seen.

Merck's Secret Weapon for Life After Keytruda

Keytruda's patent cliff is approaching fast, and Merck just unveiled early data on a two-in-one cancer antibody that could help fill a $29.5 billion hole. The response rates are competitive, but the race is crowded and the clock is ticking.